113 related articles for article (PubMed ID: 21929658)
1. Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.
Kwon MJ; Kim ST; Kwon MJ; Kong DS; Lee D; Park S; Kang SY; Song JY; Nam DH; Kato Y; Choi YL; Suh YL
Brain Pathol; 2012 May; 22(3):307-17. PubMed ID: 21929658
[TBL] [Abstract][Full Text] [Related]
2. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.
Narasimhaiah D; Miquel C; Verhamme E; Desclée P; Cosnard G; Godfraind C
Neuropathology; 2012 Feb; 32(1):30-7. PubMed ID: 21481010
[TBL] [Abstract][Full Text] [Related]
3. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
[TBL] [Abstract][Full Text] [Related]
4. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
5. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
[TBL] [Abstract][Full Text] [Related]
7. Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.
Desestret V; Ciccarino P; Ducray F; Crinière E; Boisselier B; Labussière M; Polivka M; Idbaih A; Kaloshi G; von Deimling A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2011 Nov; 105(2):219-24. PubMed ID: 21516462
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
10. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
11. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
12. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
13. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
14. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
Broniscer A; Chamdine O; Hwang S; Lin T; Pounds S; Onar-Thomas A; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
Acta Neuropathol; 2016 Feb; 131(2):299-307. PubMed ID: 26744350
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Kim D; Kim S; Kim SH; Chang JH; Yun M
Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
17. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
Divé I; Steidl E; Wagner M; Filipski K; Burger MC; Franz K; Harter PN; Bähr O; Fokas E; Herrlinger U; Steinbach JP
Oncology; 2021; 99(4):215-224. PubMed ID: 33472203
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Khan I; Waqas M; Shamim MS
J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
[TBL] [Abstract][Full Text] [Related]
19. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations of IDH1 and Vegf in brain tumors.
Veganzones S; de la Orden V; Requejo L; Mediero B; González ML; Del Prado N; Rodríguez García C; Gutiérrez-González R; Pérez-Zamarrón A; Martínez A; Maestro ML; Zimman HM; González-Neira A; Vaquero J; Rodríguez-Boto G
Brain Behav; 2017 Sep; 7(9):e00718. PubMed ID: 28948065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
